Darzalex may interfere with blood testing; Kaine scrutinized for ties to pharma; medical societies are in support of bill exempting CME reporting
Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.
Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.
While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.
Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals
Roche's blood cancer drug fails to meet trial goal; the FDA says Valeant's psoriasis drug carries risk of suicide; Facebook tests disappearing messages
U.S. companies accounted for nearly a quarter of the startups funded to celebrate Publicis' 90th anniversary.
GIlead Sciences' new HCV treatment receives approval; FDA adcomm votes in favor of Jardiance health-outcomes' claims; FDA names head of new oncology center
Think chess game rather than bare knuckle brawl.
Cancer docs push HPV vaccine; GSK says experimental lung combo trumps Symbicort; Google rolls out new symptom search feature
FDA leader says drugmakers should develop more novel drugs; Merck to acquire Afferent for $1.25 billion; Colombia demands lower prices for Gleevec
Bing can identify people with cancer symptoms; an experimental rheumatoid arthritis meets trial goals; the FDA updates compassionate use rules
Investors said a combination of Opdivo and Yervoy is the top-performing regimen in a niche of non-small cell lung-cancer patients.
Researchers question cost of multiple-myeloma combo; drugmakers say CAR-T therapies will soon be approved; the FDA approves Allergan's hypertension drug
Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.
Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices
Opdivo nets new indication; government to view Humira patent; AstraZeneca's asthma drug expected to be filed this year
Novartis breaks up pharmaceutical division and announces that David Epstein, CEO of Novartis Pharmaceuticals, will leave the company.
Using a med-tech strategy may help stem concern about CAR T-cell technology's complicated distribution and anticipated high prices, said Novartis exec.
The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.
Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance
IBM Watson Health's cognitive computing system for oncology tackles one of the leading causes of death worldwide and attempts to eradicate misdiagnoses.
Some 30% of the physicians in the U.S. sold their practices, which in turn commensurately reduced the number of physicians who are willing and able to be called on by sales reps.
The drugmaker instead suggested using an economic model it developed.
The scientific services company expands its portfolio to include expertise in oncology clinical studies.
The regulator's reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today's precision medicine.
Manufacturers team up to study drug combinations, a strategy expected to advance the category.
Bristol-Myers Squibb considered immunotherapy market leader; McKesson buys two cancer-care companies; Bayer names new CEO
Cancer MoonShot 2020 to study childhood cancers; IBM's purchase of Truven provides data about 200 million patients; overdoses tied to benzodiazepines rise
Health economic and outcomes research datasets have rarely been integral to product development and communication plans.
- Biogen ends Tecfidera DTC campaign, citing prescriptions
- As immuno-oncology therapies evolve, so will the marketing
- GSK Consumer Healthcare to prioritize digital after agency review
- Five things for pharma marketers to know: Thursday, July 21, 2016
- Five things for pharma marketers to know: Tuesday, July 26, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy
- 8 ways to improve pharma communications on Twitter
- Five things for pharma marketers to know: Thursday, July 28, 2016
- Infographic: Type 2 diabetes, a country-by-country snapshot
- Moving Forward — Without the Promotion
- Sponsored Podcast: No Patient Left Behind: Connecting Rare Disease Patients to Orphan Drug Manufacturers